BAPREFINEMENT

Bioartificial Pancreas refinement

Coordinatore	"VIVIT, VORARLBERG INSTITUTE FOR VASCULAR INVESTIGATION AND TREATEMENT- VORARLBERG INSTITUT FUR VASCULAREMEDIZIN VEREIN"    more  Organization address address: CARINAGASSE 47 city: FELDKIRCH postcode: 6800 contact info Titolo: Dr. Nome: Axel Cognome: Mündlein Email: send email Telefono: 435572000000 Fax: 4355720000000
Nazionalità Coordinatore	Austria [AT]
Totale costo	100˙000 €
EC contributo	100˙000 €
Programma	FP7-PEOPLE Specific programme "People" implementing the Seventh Framework Programme of the European Community for research, technological development and demonstration activities (2007 to 2013)
Code Call	FP7-PEOPLE-2013-CIG
Funding Scheme	MC-CIG
Anno di inizio	2014
Periodo (anno-mese-giorno)	2014-09-01   -   2018-08-31

 Partecipanti

#	participant	country	role	EC contrib. [€]
1	"VIVIT, VORARLBERG INSTITUTE FOR VASCULAR INVESTIGATION AND TREATEMENT- VORARLBERG INSTITUT FUR VASCULAREMEDIZIN VEREIN"  Organization address address: CARINAGASSE 47 city: FELDKIRCH postcode: 6800 contact info Titolo: Dr. Nome: Axel Cognome: Mündlein Email: send email Telefono: 435572000000 Fax: 4355720000000	AT (FELDKIRCH)	coordinator	100˙000.00

Mappa

 Word cloud

Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.

 Obiettivo del progetto (Objective)

'The proposed project aims at making a substantial contribution to the success of bioartificial pancreases and thus to a cure for type 1 diabetes (T1D). The latter is an autoimmune disease that destroys pancreatic beta cells which are responsible for insulin production. Mostly it strikes at a young age. Patients depend on frequent insulin injections for the rest of their life. Despite these burdensome injections, acute and long-term complications are frequent and often severe. Beta cell transplantation represents the only means of restoring physiological blood glucose control in T1D patients. But it has been hampered by a shortage of donor organs and the detrimental effects of immune suppressive medication. The latter can be circumvented by encapsulation of beta cells prior to implantation. Efforts to translate this concept of the so-called bioartificial pancreas into a clinical product have proven difficult due to poor survival of the transplanted beta cells. The current proposal aims at (1) introducing a novel type of surrogate beta cell which is much more robust than native islet cells and (2) establishing the use of an encapsulation material with superior biocompatibility. These two advancements combined are likely to improve survival and long-term functionality of the bioartificial pancreas. The researcher masterminding this project has spent the last 5 years in a bioencapsulation company in Asia’s biotech hub Singapore, most recently in the role as Chief Scientist. The host organisation, the Vorarlberg Institute for Vascular Investigation and Treatment (VIVIT), is a centre of excellence for basic and clinical research on vascular diseases and diabetes. With the researcher on board, the VIVIT is currently establishing its cell encapsulation capability and applying it to diabetes therapy. This is by far not the only area where researcher and host organisation complement each other but it is one of the most timely and relevant topics in applied diabetes research.'